| Similar Articles |
|---|
 |
The Motley Fool
August 11, 2011
Sean Williams |
Aeterna Zentaris: Out of Sight, Out of Mind Perifosine, the company's lead cancer drug, hits key milestones.   |
The Motley Fool
December 29, 2011
Brian Orelli |
What to Look for From Keryx and Aeterna Zentaris in 2012 The future is uncertain for these pharmaceutical companies. |
The Motley Fool
May 31, 2011
David Williamson |
Roundtable: The World's Best Biotechs Motley Fool analysts choose these as their favorite biotech stocks: Aeterna Zentaris... Seattle Genetics... BioMarin Pharmaceutical... Amarin... |
The Motley Fool
March 9, 2011
Brian Orelli |
Slicing and Dicing Your Way through Drug Development The drug developer announces that it licensed the Japanese rights to perifosine, its lead cancer drug, to Yakult Honsha. |
The Motley Fool
May 19, 2011
Sean Williams |
Aeterna Zentaris Continues to Deliver Positive Results The most important aspect of Aeterna Zentaris' quarterly filing is its partnership with Yakult Honsha in Japan. |
The Motley Fool
January 2, 2012
Sean Williams |
2012 Preview: Aeterna Zentaris Let's look ahead and see what will be driving Aeterna's stock price in 2012. |
The Motley Fool
October 6, 2011
Brian Orelli |
Data Published; Back to Waiting Phase 2 data for Aeterna Zentaris and Keryx's perifosine was published, but it's the phase 3 that's important. |
The Motley Fool
August 15, 2011
Jim Royal |
6 Wild Bets on Biotech Riches The most interesting biotech tickers. |
The Motley Fool
June 16, 2010
Brian Orelli |
Double-Digit Rise on Doubling Its Cash Neurocrine Biosciences is seeing a nice boost to its stock price today -- some 14% -- after Abbott Labs agreed to license its endometriosis treatment, elagolix, and any future follow-on products. |
The Motley Fool
November 11, 2011
Sean Williams |
Aeterna Zentaris Surprises Again A quarterly profit shocks analysts and me alike. |
The Motley Fool
July 29, 2011
Brian Orelli |
2 Biotechs, 1 Promising Cancer Drug Perifosine on the home stretch. |
The Motley Fool
November 28, 2011
Brian Orelli |
Breaking Down a Biotech Press Release Aeterna Zentaris: FDA Grants IND to Investigator at Baylor College of Medicine for Phase 2A Trial with AEZS-130 in Cancer Cachexia. That sure is a mouthful. Let's see if we can break it down. |
The Motley Fool
September 27, 2011
Brian Orelli |
Promising Results, But It's Still Early Aeterna Zentaris' investors got a bit of good news yesterday while they wait for phase 3 data for the company's colorectal cancer drug perifosine. |
The Motley Fool
August 30, 2011
Brian Orelli |
Aeterna Zentaris Passes Its Test AEZS-130, its diagnostic test for adult growth hormone deficiency, looks good. |
The Motley Fool
December 23, 2011
Selena Maranjian |
3 Biotech Stocks That Had a Bad 2011 It's a volatile business, and these biotechs got the short end of the stick. |
BusinessWeek
August 16, 2004
Gene G. Marcial |
Profits Loom For AEterna Zentaris The little-known Canadian biopharma has an array of cancer products that could push it to profitability after years of losses. The stock, now at $4.15, could reach $12 in a year. |
BusinessWeek
October 16, 2006
Gene G. Marcial |
Spectrum Has A Rosy Glow When Spectrum Pharmaceuticals announced on Sept. 25 that results from the Phase 3 trials of its Satraplatin were "positive," its shares bolted. |
The Motley Fool
January 18, 2012
Brian Orelli |
2 High-Flying Biotechs Face a New Hurdle The next number-one concern for Aeterna Zentaris' and Keryx's investors should be whether the drug passes its clinical trial. |
American Family Physician
March 15, 2004 |
Breast Cancer Risk Related to Type of Hormone Therapy Although several studies have demonstrated an increased risk of breast cancer in postmenopausal women taking oral hormone therapy, the risk related to each of the various forms of therapy is less clear. |
The Motley Fool
December 23, 2011
Brian Orelli |
Geron's Hurry-Up-and-Wait Strategy Clinical trials started, now the waiting begins. |
The Motley Fool
November 14, 2011
Brian Orelli |
Biotech Uncertainty = Big Upside Potential Aastrom's phase 2 and phase 3 trials don't match up. |
The Motley Fool
January 6, 2012
Brian Orelli |
Don't Read Too Much Into This Partnership While the partnership is not a sign that Roche will buy Aeterna Zentaris, there's no doubt that the development of AEZS-108 makes the biotech a more attractive takeout candidate. |
American Journal of Nursing
June 2011
Karen Roush |
Menopausal Hormone Therapy: What We Know Now This article describes the findings and limitations of the major research thus far on hormone therapy. |
Nurse Practitioner
July 2011
Kass-Wolff & Fisher |
Menopause and the Hormone Controversy: Clarification or Confusion? Hormone therapy in perimenopause and menopause remains a controversial and often confusing management strategy for healthcare providers. To assist in providing women quality healthcare, recently published new guidelines help provide direction for NPs. |
AskMen.com
Alex Santoso |
Prostate Health 101 Most men don't have any clue about their prostate -- until things go wrong. With this information, they can maximize their prostate health. |
The Motley Fool
January 18, 2012
Sean Williams |
3 Stocks Under $3 That Could Double in 2012 What these stocks lack in share price they make up for in potential. |
American Family Physician
July 1, 2002
Pamela Dull |
Managing Benign Prostatic Hyperplasia Medical and surgical options for the treatment of benign prostatic hyperplasia have expanded in recent years. |
AskMen.com
Jacob Franek |
Prostate Cancer Overview Everything you wanted to know and more about prostate cancer in this three-part prostate cancer guide. |
AskMen.com
May 27, 2002
David Dixon |
Important Information About Your Prostate Read on to learn about what men can do to protect themselves from this silent but deadly killer... |
American Family Physician
March 15, 2003
Gordon & Shaughnessy |
Saw Palmetto for Prostate Disorders Studies have demonstrated the effectiveness of saw palmetto in reducing symptoms associated with benign prostatic hyperplasia. BPH is a nearly universal result of the aging process in men. |
American Family Physician
August 15, 2006
Mounsey, Wilgus & Slawson |
Diagnosis and Management of Endometriosis The preferred method for diagnosis of endometriosis is surgical visual inspection of pelvic organs with histologic confirmation. Such diagnosis requires an experienced surgeon because the varied appearance of the disease allows less-obvious lesions to be overlooked. |
The Motley Fool
November 11, 2011
David Williamson |
Roundtable: 5 Must-Watch Stocks Highlighting companies experts are watching around the office. |
Nutrition Action Healthletter
September 2000 |
Palmetto and the Prostate Saw palmetto, botanical cure used by Native Americans to treat the symptoms of urinary tract problems, has been found to alleviate the symptoms of a swollen prostate gland, with fewer side effects than common prescription drugs... |
The Motley Fool
November 9, 2011
Sean Williams |
3 Stocks to Get on Your Watchlist It's Watchlist Wednesday, and here's what's on my radar. |
